253 related articles for article (PubMed ID: 33852840)
41. Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships.
Kunwar S; Hwang SY; Katila P; Man Kadayat T; Jung AR; Kwon Y; Lee ES
Bioorg Med Chem Lett; 2022 Mar; 60():128606. PubMed ID: 35123005
[TBL] [Abstract][Full Text] [Related]
42. DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates.
Mondal N; Parvin JD
Nature; 2001 Sep; 413(6854):435-8. PubMed ID: 11574892
[TBL] [Abstract][Full Text] [Related]
43. Topoisomerase II binds nucleosome-free DNA and acts redundantly with topoisomerase I to enhance recruitment of RNA Pol II in budding yeast.
Sperling AS; Jeong KS; Kitada T; Grunstein M
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12693-8. PubMed ID: 21771901
[TBL] [Abstract][Full Text] [Related]
44. Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3',5'-monophosphate response element-binding protein and related transcription factors.
Kroll DJ; Sullivan DM; Gutierrez-Hartmann A; Hoeffler JP
Mol Endocrinol; 1993 Mar; 7(3):305-18. PubMed ID: 8387155
[TBL] [Abstract][Full Text] [Related]
45. Inactivation of topoisomerases affects transcription-dependent chromatin transitions in rDNA but not in a gene transcribed by RNA polymerase II.
Cavalli G; Bachmann D; Thoma F
EMBO J; 1996 Feb; 15(3):590-7. PubMed ID: 8599942
[TBL] [Abstract][Full Text] [Related]
46. PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy.
Abbas A; Padmanabhan R; Romigh T; Eng C
Hum Mol Genet; 2019 Sep; 28(17):2826-2834. PubMed ID: 31127935
[TBL] [Abstract][Full Text] [Related]
47. DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin.
Liu Y; Ma J; Song JS; Zhou HY; Li JH; Luo C; Geng X; Zhao HX
Bioengineered; 2022 Feb; 13(2):2207-2216. PubMed ID: 35012441
[TBL] [Abstract][Full Text] [Related]
48. Alternative DNA secondary structure formation affects RNA polymerase II promoter-proximal pausing in human.
Szlachta K; Thys RG; Atkin ND; Pierce LCT; Bekiranov S; Wang YH
Genome Biol; 2018 Jul; 19(1):89. PubMed ID: 30001206
[TBL] [Abstract][Full Text] [Related]
49. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2.
Hangas A; Aasumets K; Kekäläinen NJ; Paloheinä M; Pohjoismäki JL; Gerhold JM; Goffart S
Nucleic Acids Res; 2018 Oct; 46(18):9625-9636. PubMed ID: 30169847
[TBL] [Abstract][Full Text] [Related]
50. Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation.
Core L; Adelman K
Genes Dev; 2019 Aug; 33(15-16):960-982. PubMed ID: 31123063
[TBL] [Abstract][Full Text] [Related]
51. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
52. Topoisomerase 2β and DNA topology during B cell development.
Papapietro O; Nejentsev S
Front Immunol; 2022; 13():982870. PubMed ID: 36045673
[TBL] [Abstract][Full Text] [Related]
53. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
54. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
[TBL] [Abstract][Full Text] [Related]
55. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
[TBL] [Abstract][Full Text] [Related]
56. Differential control of transcription-induced and overall DNA supercoiling by eukaryotic topoisomerases in vitro.
Wang Z; Dröge P
EMBO J; 1996 Feb; 15(3):581-9. PubMed ID: 8599941
[TBL] [Abstract][Full Text] [Related]
57. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.
Ju BG; Lunyak VV; Perissi V; Garcia-Bassets I; Rose DW; Glass CK; Rosenfeld MG
Science; 2006 Jun; 312(5781):1798-802. PubMed ID: 16794079
[TBL] [Abstract][Full Text] [Related]
58. A tri-serine cluster within the topoisomerase IIα-interaction domain of the BLM helicase is required for regulating chromosome breakage in human cells.
Behnfeldt JH; Acharya S; Tangeman L; Gocha AS; Keirsey J; Groden J
Hum Mol Genet; 2018 Apr; 27(7):1241-1251. PubMed ID: 29385443
[TBL] [Abstract][Full Text] [Related]
59. Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.
Büchel G; Carstensen A; Mak KY; Roeschert I; Leen E; Sumara O; Hofstetter J; Herold S; Kalb J; Baluapuri A; Poon E; Kwok C; Chesler L; Maric HM; Rickman DS; Wolf E; Bayliss R; Walz S; Eilers M
Cell Rep; 2017 Dec; 21(12):3483-3497. PubMed ID: 29262328
[TBL] [Abstract][Full Text] [Related]
60. Phosphorylation of histone H3 at Ser10 facilitates RNA polymerase II release from promoter-proximal pausing in Drosophila.
Ivaldi MS; Karam CS; Corces VG
Genes Dev; 2007 Nov; 21(21):2818-31. PubMed ID: 17942706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
